The focus for therapeutic intervention in psoriasis is currently on modulating inflammatory immune parameters such as IL-17, IL-12, IL-23, or TNF (Lowes et al., 2013), which are the immune drivers of skin pathology in both human disease and the mouse model. Here, TNF is linked to psoriasis.